New $32M round helps APT battle lung transplant rejection
APT Pharmaceuticals Inc. announced today that it has raised $32 million in its second round from a flock of investors led by Three Arch Partners, and including InterWest Partners, Pinnacle Ventures, Charter Life Sciences, Great Point Partners, Versant Ventures and Vivo Ventures.
APT, headquartered in Burlingame, Calif., develops drugs to combat lung diseases. Currently, the spotlight is on a compound that could prevent lung transplant rejection. The company plans to use the $55 million brought in… Continue Reading
Life sciences briefing: Thursday, Oct. 4, 2007
Featured companies: 23andMe, APT Pharmaceuticals, Hyperion Therapeutics, Isis Biopolymer, Virogenomics
UPDATED at 10:30am PT.
APT Pharma raises $22M for transplant and heart drugs — Burlingame, Calif.’s APT Pharmaceuticals, a specialty pharma currently focused on a drug to fight organ-transplant rejection, raised $22 million in an extension of its first funding round. Investors included Versant Ventures, Great Point Partners, Vivo Ventures and Charter Life Sciences.
APT, which acquires its drug candidates instead of developing them itself, has raised a total of… Continue Reading